Get startedLog in
    Picture of Clinuvel Pharmaceuticals logo

    CUV — Clinuvel Pharmaceuticals News Story

    0.000.00%
    au flag iconLast trade - 00:00
    HealthcareBalancedSmall CapContrarian
    All News

    Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug

    Picture of Clinuvel Pharmaceuticals logoClinuvel Pharmaceuticals
    13/07/2026 01:58
    BUZZ-Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
    ** Shares of Clinuvel Pharmaceuticals CUV.AX rise as much as 4.6% to A$10.74, marking their highest level since June 30
    ** Health Canada approves co's SCENESSE drug for treating phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare metabolic disorder
    ** Approval allows co to market and sell SCENESSE in Canada
    ** Stock down 16.6% YTD

     (Reporting by Jasmeen Ara Shaikh in Bengaluru)
     ((Jasmeenaraislam.Shaikh@thomsonreuters.com;))

    Recent news on Clinuvel Pharmaceuticals

    See all news